Publicaciones científicas
Treatment of Primary Nummular Headache: A Series of 183 Patients from the NUMITOR Study
Cristina García-Iglesias 1 , Francesca Puledda 2 , Ana Echavarría-Íñiguez 1 , Yesica González-Osorio 1 , Álvaro Sierra-Mencía 1 , Andrea Recio-García 1 , Ana González-Celestino 1 , Gonzalo Valle-Peñacoba 1 , Pablo Irimia 3 , Ángel Luis Guerrero-Peral 1 4 , David García-Azorín 1 4
Abstract
Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients.
The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study.
Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters' diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients.
The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9-25%.
The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH.
CITA DEL ARTÍCULO J Clin Med. 2022 Dec 23;12(1):122. doi: 10.3390/jcm12010122
Nuestros autores
